A similar effect was observed in models of colon adenocarcinoma, fibrosarcoma, ovarian tumors, melanomas, lymphomas, and multiple myelomas, where the mice were treated with one antibody or with combination targeting LAG-3/PD-1 compounds. Here, LAG3 is linked to melanoma.